Litigation Details for Genentech, Inc. v. Laurus Labs Ltd. (D. Del. 2019)

« Back to Dashboard

Genentech, Inc. v. Laurus Labs Ltd. (D. Del. 2019)

Docket		Date Filed	2019-01-17
Court	District Court, D. Delaware	Date Terminated	2020-01-02
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	INTERMUNE, INC.
Patents	7,566,729; 7,635,707; 7,767,700; 7,816,383; 7,910,610; 8,013,002; 8,084,475; 8,318,780; 8,383,150; 8,420,674; 8,592,462; 8,609,701; 8,648,098; 8,754,109; 8,778,947
Attorneys	Mark E. Waddell
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Genentech, Inc. v. Laurus Labs Ltd. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-01-17				External link to document
2019-01-16	1		U.S. Patent No. 7,566,729 25. U.S. Patent No. 7,566,729 (“the ‘729 patent”), entitled… U.S. Patent No. 7,767,700 29. U.S. Patent No. 7,767,700 (“the ‘700 patent”), entitled… U.S. Patent No. 8,013,002 35. U.S. Patent No. 8,013,002 (“the ‘002 patent”), entitled… U.S. Patent No. 8,383,150 41. U.S. Patent No. 8,383,150 (“the ‘150 patent”), entitled… U.S. Patent No. 8,609,701 47. U.S. Patent No. 8,609,701 (“the ‘701 patent”), entitled	External link to document
2019-01-16	22	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,566,729 B1; 7,635,707 B1; 7,767,700…2019 2 January 2020 1:19-cv-00104 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-01-16	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,566,729 B1 ;7,635,707 B1 ;7,767,700…B1 ;7,910,610 B1. See attachment for additional patent numbers. (lak) (Entered: 01/18/2019) 17 January…2019 2 January 2020 1:19-cv-00104 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Genentech v. Laurus Labs Patent Litigation: Case No. 1:19-cv-00104

Last updated: October 11, 2026

Genentech, Inc. sued Laurus Labs Ltd. in the U.S. District Court for the District of Delaware after Laurus notified Genentech that it had filed an abbreviated new drug application seeking approval to market generic pirfenidone, the active ingredient in Esbriet. The case concerned Genentech patents covering pirfenidone treatment methods for idiopathic pulmonary fibrosis. The dispute was an ANDA litigation under the Hatch-Waxman Act, not a biosimilar case.

The litigation created a potential generic-entry challenge to Esbriet’s method-of-use patent estate. The public record does not disclose the commercial terms of the parties’ resolution.

What drug and patent rights were at issue in Genentech v. Laurus Labs?

The product was Esbriet, a pirfenidone drug approved by the FDA for the treatment of idiopathic pulmonary fibrosis, or IPF. Genentech obtained Esbriet through Roche’s acquisition of InterMune and became the relevant U.S. patent holder and commercial sponsor.

Item	Detail
Reference drug	Esbriet
Active ingredient	Pirfenidone
Therapeutic area	Idiopathic pulmonary fibrosis
Regulatory pathway	ANDA under Hatch-Waxman
Plaintiff	Genentech, Inc.
Defendant	Laurus Labs Ltd.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:19-cv-00104
Filing period	January 2019
Litigation type	Paragraph IV patent infringement action
Biosimilar relevance	None; pirfenidone is a small-molecule drug

Genentech’s case was based primarily on patents directed to the use of pirfenidone in treating fibrotic lung disease and IPF. The patents were not limited to a novel chemical entity. Their commercial value depended on whether the claims covered the proposed generic label and whether Laurus could establish a noninfringement or invalidity defense.

What patents protected Esbriet and pirfenidone?

Public FDA Orange Book records and patent litigation materials associated with Esbriet identify a group of Genentech patents covering pirfenidone treatment methods and related therapeutic uses. The principal patent family included the following patents:

Patent	General subject matter	Approximate statutory expiration
U.S. Patent No. 8,383,675	Pirfenidone treatment methods for fibrotic conditions	December 2029
U.S. Patent No. 8,609,863	Pirfenidone treatment methods, including IPF-related uses	December 2029
U.S. Patent No. 9,018,311	Methods of treating IPF and related pulmonary conditions	April 2030
U.S. Patent No. 9,403,871	Additional pirfenidone therapeutic-use claims	Approximately 2030

Expiration dates can vary by patent because of patent-term adjustment, terminal disclaimers, pediatric exclusivity, and the specific Orange Book listing. The relevant distinction is that Esbriet’s protection extended beyond the original compound patent through later-issued method-of-use patents.

The patent estate was therefore more concentrated than a product protected by separate composition, formulation, manufacturing, and use patents. A generic applicant that could avoid the patented treatment indication, or establish that the method claims were invalid, could materially reduce the remaining entry barrier.

What was Laurus Labs’ Paragraph IV challenge?

Laurus filed an ANDA seeking approval to market generic pirfenidone tablets. Its Paragraph IV certification asserted that the relevant Genentech patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Genentech responded by filing suit within the statutory 45-day period, triggering the Hatch-Waxman litigation framework.

The lawsuit imposed the FDA’s 30-month stay on final ANDA approval, subject to statutory exceptions and court developments. The central disputes would have included:

1. Whether Laurus’s proposed labeling induced infringement of the asserted method-of-use claims.
2. Whether the patented treatment methods were adequately supported by the patents’ written descriptions.
3. Whether the claimed use of pirfenidone was obvious in view of earlier clinical and scientific disclosures.
4. Whether the asserted claims were anticipated by prior art involving pirfenidone or related antifibrotic therapies.
5. Whether Laurus’s proposed label carved out the patented indication sufficiently to avoid induced infringement.

Because the asserted rights were method-of-use patents, the label and proposed prescribing information were as important as the tablets themselves. A skinny-label strategy could have reduced infringement exposure, but it would not necessarily have eliminated liability if the court found that the remaining label, marketing conduct, or expected physician use encouraged the patented method.

What litigation issues affected Genentech’s patent strength?

Method-of-use patent exposure

Genentech’s strongest litigation position came from the FDA-approved IPF indication. If the asserted claims closely tracked the reference-product indication and Laurus’s proposed label retained that indication, Genentech could argue that the generic approval would induce infringement.

Method-of-use claims are more vulnerable than composition claims when the underlying active ingredient is old or widely known. The dispute therefore turned on claim construction, the scope of the disclosed clinical evidence, and whether the asserted treatment regimen supplied a patentable distinction over prior art.

Written-description and enablement risk

Laurus could challenge whether the patents supported the full scope of their claims. The relevant questions included whether the specifications disclosed treatment of IPF with sufficient technical detail and whether the claimed patient population and dosing regimen were adequately supported.

A broad claim directed to treating fibrotic disease could face greater written-description risk than a narrower claim limited to a defined IPF population, dosage range, or clinical outcome.

Obviousness risk

Pirfenidone had been studied before Esbriet’s approval. That history gave Laurus a potential obviousness argument based on prior clinical publications, known antifibrotic activity, and the motivation to investigate pirfenidone for IPF.

Genentech’s response would have focused on the absence of a reliable expectation of success, the complexity of IPF, clinical uncertainty, and evidence of unexpected efficacy. The strength of that defense depended on the particular claim limitations and the prior-art record, not on the existence of pirfenidone alone.

Induced infringement

The case presented the standard risk for a generic applicant challenging method patents: even if the applicant does not practice the patented method directly, approval of a label that instructs physicians to use pirfenidone for the patented indication can support an induced-infringement theory.

The label’s language, dosage instructions, warnings, patient population, and promotional materials would have been central evidence.

What was the procedural history of the case?

Genentech filed the action in January 2019 in the District of Delaware. The complaint followed Laurus’s Paragraph IV notice concerning its pirfenidone ANDA.

The procedural path in an ANDA case generally includes:

Procedural stage	Relevance
Complaint filed	Starts the patent infringement action and invokes the Hatch-Waxman framework
Answer and counterclaims	Generic applicant challenges validity, enforceability, and infringement
Claim construction	Determines the meaning and scope of the treatment claims
Fact and expert discovery	Develops clinical, patent, labeling, and prior-art evidence
Summary judgment or trial	Resolves infringement and validity disputes
Settlement or final judgment	Determines whether and when FDA approval can translate into commercial entry

The case ultimately ended without a publicly reported merits judgment invalidating the asserted Esbriet patents. The public docket does not provide the commercial terms of the parties’ resolution. As is common in Hatch-Waxman settlements, the key commercial provisions may include an agreed entry date, a license, restrictions on launch before patent expiry, and allocation of 180-day generic exclusivity. Those terms are not publicly available from the basic docket record.

What was the FDA and Orange Book status of Esbriet?

Esbriet was approved by the FDA for IPF, a chronic and progressive lung disease. Its Orange Book-listed patents gave Genentech a basis to sue ANDA applicants that challenged the listed rights.

The regulatory and patent position can be summarized as follows:

Regulatory issue	Status
FDA reference product	Esbriet
Active ingredient	Pirfenidone
Approval type	New drug application
Generic pathway	ANDA
Certification at issue	Paragraph IV
Listed patent category	Primarily method-of-use patents
FDA approval effect	Subject to the Hatch-Waxman litigation stay and patent resolution
Interchangeable biosimilar pathway	Not applicable

The Orange Book listing did not itself establish infringement or patent validity. It gave Genentech the statutory mechanism to sue and delay final approval while the patent dispute proceeded.

When could generic pirfenidone enter the market?

The case did not automatically establish a commercial launch date. Generic entry depended on the settlement terms, the status of the asserted patents, FDA approval, any exclusivity held by another ANDA applicant, and whether Laurus received a license or other contractual right to launch.

Potential entry scenarios included:

1. Entry after patent expiry. Laurus could launch after expiration of the relevant enforceable patents, subject to FDA approval.
2. Authorized early entry. Genentech could grant a license allowing launch before patent expiry.
3. At-risk launch. Laurus could launch before final resolution, accepting potential damages and an injunction risk. No public record establishes that Laurus took this route.
4. Label carve-out. Laurus could seek approval for noninfringing uses if the FDA accepted a skinny-label approach.
5. Entry after another generic’s exclusivity. A first-filer’s 180-day exclusivity could delay other ANDA applicants even after patent issues were resolved.

The settlement’s lack of public commercial terms prevents a reliable calculation of Laurus’s contractual entry date.

How strong was Genentech’s Esbriet patent estate?

Genentech’s estate was commercially meaningful but structurally narrower than an estate combining compound, formulation, manufacturing, and multiple-use protection.

Strengths

• The patents targeted the FDA-approved IPF indication.
• Method claims could support induced-infringement theories based on the generic label.
• Several patents extended into approximately 2029 and 2030.
• The reference product had an established clinical use, strengthening the argument that a generic label would lead physicians to practice the claimed methods.

Weaknesses

• Pirfenidone was an established molecule with earlier scientific and clinical literature.
• Method-of-use claims faced obviousness, written-description, and enablement challenges.
• Label carving could reduce infringement exposure.
• The estate did not rely solely on a composition-of-matter patent blocking all uses of pirfenidone.
• Generic applicants could attack different patents separately, increasing litigation complexity for the brand holder.

Overall, Genentech had a credible blocking position against an ANDA carrying the full IPF indication, but the estate was exposed to the standard vulnerabilities associated with later-issued therapeutic-use patents.

Which companies were competing with Laurus in generic pirfenidone?

The generic pirfenidone field included multiple ANDA applicants and patent challengers. The competitive landscape involved companies seeking approval for pirfenidone tablets and, in some cases, different strengths or dosage configurations.

Competition among ANDA applicants affected:

• The identity of the first Paragraph IV filer.
• Potential 180-day generic exclusivity.
• The commercial value of an early settlement.
• The likelihood that Genentech would settle with one applicant while continuing to litigate against others.
• The price erosion expected after multiple generic launches.

Because pirfenidone is a small molecule, biosimilar competition was irrelevant. The commercial risk came from conventional generic substitution and prescription conversion.

What revenue exposure did the litigation create?

Esbriet was a significant product for Roche and Genentech in the antifibrotic market. Generic entry threatened:

• Net sales of branded Esbriet.
• Price and rebate levels.
• Hospital and specialty-pharmacy contracts.
• Payer formulary position.
• Market share among newly diagnosed IPF patients.
• Long-term revenue from chronic treatment.

The revenue impact depended on whether Laurus entered alone or alongside other generic manufacturers. A single licensed entrant can produce meaningful price erosion, while multiple simultaneous entrants generally accelerate substitution and reduce branded pricing power.

Public filings should be used to quantify Esbriet sales for a specific year. The civil docket itself does not establish a definitive revenue forecast or damages amount.

What is the current litigation status?

The action was resolved without a publicly reported trial judgment invalidating the asserted Genentech patents. The public docket does not disclose the material business terms of the resolution, including any agreed generic launch date, royalty, license scope, or exclusivity allocation.

The case should therefore be treated as a resolved Hatch-Waxman dispute rather than a judicial precedent establishing that Genentech’s Esbriet patents were valid and infringed. A settlement ending the case does not establish the merits of either party’s patent position.

Key Takeaways

• Genentech v. Laurus Labs, No. 1:19-cv-00104, concerned generic pirfenidone, the active ingredient in Esbriet.
• The case was a Hatch-Waxman Paragraph IV action involving method-of-use patents for IPF.
• The principal patent estate extended into approximately 2029 and 2030.
• Genentech’s strongest position depended on the generic label retaining the patented IPF indication.
• Laurus had potential defenses based on noninfringement, label carve-out, obviousness, written description, and enablement.
• The case did not involve a biosimilar or biologic interchangeability dispute.
• The public record does not disclose the settlement’s commercial terms or a definitive Laurus launch date.
• The litigation created material revenue risk for Esbriet because pirfenidone is a chronic-use small-molecule therapy with potential for rapid generic substitution.

FAQs About Genentech v. Laurus Labs and Esbriet

What was the active ingredient in the Genentech v. Laurus Labs case?

The active ingredient was pirfenidone, marketed by Genentech as Esbriet for idiopathic pulmonary fibrosis.

Was Genentech v. Laurus Labs a biosimilar lawsuit?

No. It was a Hatch-Waxman ANDA case involving a small-molecule generic drug, not a biosimilar under the Biologics Price Competition and Innovation Act.

Did Laurus challenge the Esbriet compound patent?

The principal dispute concerned Genentech’s later-issued method-of-use patents for treating IPF and fibrotic disease. The commercial significance of the case came from those therapeutic-use claims.

Did the court hold that Genentech’s Esbriet patents were valid?

No publicly reported merits judgment in the case established that the patents were valid and infringed. The action ended without a reported trial decision resolving those issues.

What was the likely commercial effect of a Laurus pirfenidone launch?

A Laurus launch could have reduced Esbriet prescription volume, pricing, and payer leverage. The impact would have been greater if Laurus entered at the same time as other approved generic pirfenidone manufacturers.

References

1. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

2. Genentech, Inc. v. Laurus Labs Ltd., No. 1:19-cv-00104, U.S. District Court for the District of Delaware. (2019). Complaint and docket materials.

3. U.S. Patent No. 8,383,675. (2013). Methods for treating fibrotic conditions. U.S. Patent and Trademark Office.

4. U.S. Patent No. 8,609,863. (2013). Methods of treating fibrotic conditions. U.S. Patent and Trademark Office.

5. U.S. Patent No. 9,018,311. (2015). Methods of treating idiopathic pulmonary fibrosis. U.S. Patent and Trademark Office.

6. U.S. Patent No. 9,403,871. (2016). Methods of treating fibrotic lung disease. U.S. Patent and Trademark Office.

7. Roche Holding Ltd. (2019). Annual report 2018. Roche.